Effects and management of the menopausal transition in women with depression and bipolar disorder

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 9, 2007, Pages 16-21

  Soares, Claudio N ^a,b,c,d   Taylor, Valerie ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b Women's Health Concerns Clinic   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; HERBACEOUS AGENT; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; PAROXETINE; PROGESTERONE; VALPROIC ACID; VENLAFAXINE; NEUROLEPTIC AGENT;

AGITATION; ANXIETY; BIPOLAR DISORDER; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL EXAMINATION; DEMENTIA; DEPRESSION; DISTRESS SYNDROME; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL DISORDER; EPILEPSY; FRACTURE; HEALTH STATUS; HIGH RISK POPULATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERPARATHYROIDISM; MAJOR DEPRESSION; MONOTHERAPY; MOOD DISORDER; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; STANDARD; STROKE; SYMPTOMATOLOGY; UNITED STATES; WELLBEING; WOMEN'S HEALTH; AFFECT; AGE; FEMALE; MENOPAUSE; PATHOPHYSIOLOGY;

AFFECT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; FEMALE; HUMANS; MENOPAUSE; QUALITY OF LIFE;

EID: 35348977860     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Michaud CM, Murray CJ, Bloom BR. Burden of disease: implications for future research. JAMA 2001;285:535-539. Correction 2001;286:1833-1835
2. Barnes C, Mitchell P. Considerations in the management of bipolar disorder in women. Aust N Z J Psychiatry 2005;39:662-673
3. Goodnick PJ, Chaudry T, Artadi J, et al. Women's issues in mood disorders. Expert Opin Pharmacother 2000;1:903-916
4. Arnold LM, McElroy SL, Keck PE Jr. The role of gender in mixed mania. Compr Psychiatry 2000;41:83-87
5. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004;6:2-13
6. Santoro N. The menopausal transition. Am J Med 2005;118(12 suppl 2):8-13
7. Soules MR, Sherman S, Parrott E, et al. Executive summary: stages of reproductive aging workshop (STRAW). Fertil Steril 2001;76:874-878
8. Sherman S. Defining the menopausal transition. Am J Med 2005;118(12 suppl 2):3-7
9. US Census Bureau. Female population by age, race, and Hispanic or Latin origin for the United States: census 2000. PHC-T-9. Oct 3, 2001. Available at www.census.gov/population/www/cen2000/phc-t-9.html. Accessed May 24, 2006
10. Soares CN, Prouty J, Bom L, et al. Treatment of menopause-related mood disturbances. CNS Spectr 2005;10:489-497
11. Cohen LS, Soares CN, Joffe H. Diagnosis and management of mood disorders during the menopausal transition. Am J Med 2005;118(12 suppl 2):93-97
12. Soares CN, Cohen LS. The perimenopause and mood disturbances: an update. CNS Spectr 2001;6:167-174
13. Dennerstein L, Dudley E, Guthrie J. Empty nest or revolving door? a prospective study of women's quality of life in midlife during the phase of children leaving and re-entering the home. Psychol Med 2002;32:545-550
14. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473
15. Cappola AR, Xue QL, Ferrucci L, et al. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003;88:2019-2025
16. Bandinelli S, Lauretani F, Benvenuti E, et al. Understanding the physiological and functional consequences of menopause: the PROSALMEN study. PROgetto SALute MENopausa. Aging Clin Exp Res 2002;14:170-177
17. Fuh JL, Wang SJ, Lu SR, et al. Alterations in cognitive function during the menopausal transition [letter]. J Am Geriatr Soc 2003;51:431-432
18. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238-2244
19. Freeman EW, Sammel MD, Liu L, et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70
20. Cohen LS, Soares CN, Vitonis AF, et al. Risk of new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2006;63:385-390
21. Joffe H, Soares CN, Cohen LS. Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatr Clin North Am 2003;26:563-580
22. Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health 2001;91:1435-1442
23. Freeman MP, Smith KW, Freeman SA, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002;63:284-287
24. Wehr T, Sack D, Rosenthal N, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145:179-184
25. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156-167
26. Blehar MC, DePaulo JR Jr, Gershon ES, et al. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull 1998;34:239-243
27. Matthews KA, Bromberger JT. Does the menopausal transition affect health-related quality of life? Am J Med 2005;118(12 suppl 2):25-36
28. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
29. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662
30. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-2968
31. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-420
32. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-534
33. Rasgon NL, Altshuler LL, Fairbanks L. Estrogen-replacement therapy for depression [letter]. Am J Psychiatry 2001;158:1738
34. Cohen LS, Soares CN, Poitras JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003;160:1519-1522
35. Morrison MF, Kalian MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004;55:406-412
36. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834
37. Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-166
38. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinylestradiol and norethindrone acetate for symptomatic peri and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13:780-786
39. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7(suppl 3):5-69
40. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med 1996;335:1176-1181
41. Whooley MA, Kip EK, Cauley JA, et al. Depression, falls, and risk of fracture in older women. Arch Intern Med 1999;159:484-490
42. Reginster JY, Deroisy R, Paul I, et al. Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 1999;33:133-137
43. Ali II, Schuh L, Barkley GL, et al. Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav 2004;5:296-300
44. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8:339-342
45. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262
46. Misra M, Papakostas GI, Klibansi A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65:1607-1618
47. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-257